糖尿病与动脉粥样硬化性心血管疾病改变可溶性肿瘤坏死因子受体1与脓毒症死亡率的关联:一项二次队列分析
该研究为二次队列分析,纳入466例脓毒症合并呼吸衰竭或血管升压药依赖休克且基线有sTNFR1测量的成人患者。243例(52.1%)合并糖尿病或ASCVD。校正疾病严重度、年龄三分位和性别后,无糖尿病或ASCVD者sTNFR1每升高1个标准差,90天死亡风险HR 2.25(95%CI 1.76-2.88);合并糖尿病或ASCVD者关联减弱,sTNFR1约12000 pg/mL以上死亡风险出现平台,总体HR 1.04(95%CI 0.83-1.30),交互p<0.001。该交互仅见于sTNFR1,未见于IL-6或angiopoietin-2。提示合并症可改变生物标志物与结局的生物学关系,影响生物标志物指导的风险分层。
要点
- 在脓毒症合并呼吸衰竭或血管升压药依赖休克成人中,无糖尿病或ASCVD者sTNFR1每升高1个标准差与90天死亡率相关(HR 2.25,95%CI 1.76-2.88)。
- 合并糖尿病或ASCVD者sTNFR1与90天死亡率的关联减弱,sTNFR1约12000 pg/mL以上死亡风险出现平台(总体HR 1.04,95%CI 0.83-1.30;交互p<0.001)。
- 尽管两组疾病严重度和死亡率相似,合并糖尿病或ASCVD者sTNFR1中位数更高(6547 vs. 4883 pg/mL)。
- 该效应修饰仅见于sTNFR1,未见于白细胞介素-6或血管生成素-2;单纯肥胖或高血压无糖尿病或ASCVD者未见效应修饰。
- 临床解读sTNFR1用于脓毒症风险分层时需考虑糖尿病或ASCVD合并症,避免在高sTNFR1合并这些疾病时高估死亡风险。
适用人群与场景
- 美国学术医院中466例成人脓毒症患者,合并呼吸衰竭或血管升压药依赖休克,且基线有sTNFR1测量。
- 二次分析基于Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery Research Materials。
诊断标准与关键阈值
- 糖尿病或ASCVD依据Charlson合并症分类定义。
- sTNFR1与90天死亡率关联的交互分析采用Cox回归限制性立方样条,校正疾病严重度、年龄三分位和性别。
- sTNFR1约12000 pg/mL以上死亡风险出现平台(原文描述)。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型为二次队列分析,样本量466例,来自美国学术医院,无干预。
- 243例(52.1%)合并糖尿病或ASCVD;两组疾病严重度和死亡率相似。
- 无糖尿病或ASCVD者sTNFR1每升高1个标准差,90天死亡率HR 2.25(95%CI 1.76-2.88)。
- 合并糖尿病或ASCVD者关联减弱,sTNFR1约12000 pg/mL以上风险平台,总体HR 1.04(95%CI 0.83-1.30),交互p<0.001。
- 该交互仅见于sTNFR1,未见于IL-6或angiopoietin-2;肥胖或高血压无糖尿病或ASCVD者无效应修饰。
证据类型、等级与局限
- 证据类型为二次队列分析(原文标注Secondary cohort analysis)。
- 局限:二次分析、样本量466例、仅美国学术医院、无干预、sTNFR1单次基线测量。
对床旁实践的改变
- 在脓毒症合并呼吸衰竭或血管升压药依赖休克成人中,解读sTNFR1风险分层时需考虑糖尿病或ASCVD合并症对关联的减弱作用。
- 不适用于无糖尿病或ASCVD的脓毒症患者以外人群的sTNFR1阈值判断;原文未提供临床决策阈值。
- 常见陷阱:将sTNFR1在合并糖尿病或ASCVD者中的平台效应误读为与死亡率无关,或忽略合并症对生物标志物-结局关系的影响。
指南或共识出处
- Diabetes and Atherosclerotic Cardiovascular Disease Modify the Association Between Soluble Tumor Necrosis Factor Receptor 1 and Sepsis Mortality: A Secondary Cohort Analysis(Crit Care Med)。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine whether diabetes mellitus or atherosclerotic cardiovascular disease (ASCVD) modify the association between soluble tumor necrosis factor receptor 1 (sTNFR1) and mortality in sepsis.
DESIGN: Secondary cohort analysis using the Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery Research Materials.
SETTING: Academic hospitals in the United States.
PATIENTS: A total of 466 adults with sepsis and respiratory failure or vasopressor-dependent shock with available baseline sTNFR1 measurements.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We tested the interaction between sTNFR1 and diabetes or ASCVD (defined by Charlson comorbidity categories) on 90-day mortality using Cox regression with restricted cubic splines, adjusted for illness severity, age (in tertiles), and sex. Of 466 patients, 243 patients (52.1%) had diabetes or ASCVD. Despite similar illness severity and mortality between groups, sTNFR1 was higher among patients with diabetes or ASCVD (median, 6547 vs. 4883 pg/mL). Among patients without diabetes or ASCVD, higher sTNFR1 was associated with 90-day mortality (hazard ratio [HR], 2.25 per sd; 95% CI, 1.76-2.88). The association was attenuated among those with diabetes or ASCVD, with a plateau in mortality risk above approximately 12,000 pg/mL (overall HR, 1.04; 95% CI, 0.83-1.30; interaction p < 0.001). This interaction was specific to sTNFR1 and was not observed for interleukin-6 or angiopoietin-2. No effect modification was present among patients with obesity or hypertension without diabetes or ASCVD.
CONCLUSIONS: Diabetes or ASCVD attenuated the association between sTNFR1 and sepsis mortality. These findings suggest that comorbid conditions may alter the biological relationship between a biomarker and outcome, with implications for biomarker-guided risk stratification and disease mechanisms in sepsis.
参考来源
- Gaulton TG, Rigsby R, Shapiro NI, et al. Diabetes and Atherosclerotic Cardiovascular Disease Modify the Association Between Soluble Tumor Necrosis Factor Receptor 1 and Sepsis Mortality: A Secondary Cohort Analysis. Crit Care Med. 2026. PMID: 42813914. doi:10.1097/CCM.0000000000007374
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。